A phase 2 pharmacokinetic trial of dovitinib (TKI258) in Asian and non-Asian patients with metastatic renal cell carcinoma

Trial Profile

A phase 2 pharmacokinetic trial of dovitinib (TKI258) in Asian and non-Asian patients with metastatic renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2015

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Renal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 06 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top